Arrowhead Pharmaceuticals
(NASDAQ) ARWR
Arrowhead Pharmaceuticals Financials at a Glance
Market Cap
$12.25BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Revenue (TTM)
$622.01M
Net Income (TTM)
-$300.91M
EPS (TTM)
-$2.15
P/E Ratio
-40.48
Dividend
$0.00
Beta (Volatility)
1.67 (High)
Dividend
$0.00
Beta (Volatility)
1.67 (High)
Price
$86.91
Volume
67,391
Open
$86.77
Price
$86.91
Volume
67,391
Open
$86.77
Previous Close
$86.91
Daily Range
$83.86 - $87.52
52-Week Range
$14.30 - $87.83
Estimated Earnings Date
Aug 6, 2026
Dividend
$0.00
Beta (Volatility)
1.67 (High)
Price
$86.91
Volume
67,391
Open
$86.77
Previous Close
$86.91
Daily Range
$83.86 - $87.52
52-Week Range
$14.30 - $87.83
Estimated Earnings Date
Aug 6, 2026
ARWR News
ARWR: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Arrowhead Pharmaceuticals
Industry
Biotechnology
Sector
Health CareEmployees
711
CEO
Christopher Richard Anzalone, PhD
Website
www.arrowheadpharma.comHeadquarters
Pasadena, CA 91105, US
ARWR Financials
Key Financial Metrics (TTM)
Gross Margin
100.00%
Operating Margin
-35.67%
Net Income Margin
-48.38%
Return on Equity
-55.45%
Return on Capital
11.82%
Return on Assets
-13.27%
Earnings Yield
-2.47%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$12.25BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Shares Outstanding
140.86M
Volume
67.39K
Avg. Volume
2.07M
Financials (TTM)
Gross Profit
$622.01M
Operating Income
-$221.90M
EBITDA
-$134.47M
Operating Cash Flow
-$36.31M
Capital Expenditure
-$14.57M
Free Cash Flow
-$50.87M
Cash & ST Invst.
$1.78B
Total Debt
$1.37B
Arrowhead Pharmaceuticals Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$73.74M
-86.4%
Gross Profit
$73.74M
-86.4%
Gross Margin
100.00%
N/A
Market Cap
$12.25BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
N/A
Market Cap/Employee
$20.12M
N/A
Employees
609
N/A
Net Income
-$132.73M
-135.8%
EBITDA
-$107.35M
-127.0%
Quarterly Fundamentals
Total Cash
$1.78B
+62.6%
Total Debt
$1.37B
+85.5%
Accounts Receivable
$15.69M
+563.2%
Inventory
$0.00
N/A
Long Term Debt
$1.33B
+98.2%
Short Term Debt
$47.77M
-33.4%
Return on Assets
-13.27%
N/A
Return on Invested Capital
-11.25%
N/A
Free Cash Flow
$81.88M
-82.0%
Operating Cash Flow
$84.44M
-81.6%